The short version of thymic extract fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Differenzierung (von lateinisch differre ‚sich unterscheiden‘) bezeichnet in der Entwicklungsbiologie die Entwicklung von Zellen oder Geweben von einem weniger in einen stärker spezialisierten Zustand. Es handelt sich hierbei um einen artspezifisch vielfach irreversiblen und daher prädeterminiert erscheinenden Wandel von einzelnen Zellen und Geweben. Dieser Wandel kann in unterschiedlichen (polyvalenten) Richtungen erfolgen. Krankheitsbedingt kann es zur Rückbildung der entwicklungsgeschichtlich erfolgten Aufbauleistungen zugunsten primitiverer Stadien kommen, was dann als Entdifferenzierung bezeichnet wird. Differenzierungsprozesse treten einerseits bei der individuellen Entwicklung eines vielzelligen Organismus auf, der sich aus einer Zygote zu einem komplexen Gebilde mit vielen verschiedenen Zelltypen und Gewebetypen entwickelt. Auch in ausgewachsenen Individuen spielen Differenzierungsprozesse wichtige Rollen bei der Aufrechterhaltung der Körperfunktionen. Die Differenzierung ist zusammen mit der Zellteilung verantwortlich dafür, einem mehrzelligen Lebewesen seine Form zu verleihen, die Gesamtheit dieses Prozesses wird als Morphogenese bezeichnet.
== Steuerung der Differenzierung durch Genregulation == Molekularbiologisch äußert sich die Differenzierung von Zellen darin, dass nicht das gesamte Genom exprimiert, also in Proteine umgesetzt, wird, sondern nur die für den jeweiligen Zelltyp benötigten Gene aktiv sind. Im Gegensatz zur kurzfristig variablen Genexpression, die zum Beispiel die Reaktion auf Hormone oder Stress erlaubt, stellt die Differenzierung also eine längerfristig stabile Form der Genregulation dar.
== Differenzierung und Determination == Bei Lebewesen mit sexueller Fortpflanzung beginnt die Entwicklung mit einer einzigen Zelle, der befruchteten Eizelle (Zygote), welche alle Zelltypen des vollständigen Organismus hervorbringen kann. Diese Eigenschaft wird als „Totipotenz“ bezeichnet (von lat. totus – alles und potentia – Macht, Fähigkeit). Durch Zellteilung gehen aus dieser mehrere Tochterzellen hervor, die sich je nach Zellabstammung auf verschiedene Rollen spezialisieren. Insbesondere bei Tieren geht dieser Vorgang mit der sogenannten Determination einher. Das bedeutet, dass die eingeschlagene Richtung der Spezialisierung auf nachfolgende Zellgenerationen auf epigenetischem Weg weitergegeben wird. Eine determinierte Zelle behält damit ihr Entwicklungsprogramm auch dann bei, wenn sie zum Beispiel an einen anderen Ort innerhalb des Organismus verpflanzt wird. Hierdurch schränkt sich die Potenz der Zelllinie immer weiter ein, von pluripotenten embryonalen Stammzellen (von lat. pluriens – mehrfach), welche alle Zelltypen des Embryos hervorbringen können, über multipotente Körperstammzellen („somatische Stammzellen“, lat. multus – viel bzw. altgriechisch σῶμα soma, deutsch ‚Körper‘), welche nur die Zelltypen eines bestimmten Gewebes hervorbringen können, bis zu irreversibel differenzierten, funktionellen Körperzellen. Diese verlieren meist die Teilungsfähigkeit und haben häufig nur eine begrenzte Lebensdauer.
Allerdings können Zellen unter bestimmten Umständen ihre Determination ändern (Transdetermination), ihre Differenzierung verlieren (Dedifferenzierung) oder sich nach einer Dedifferenzierung neu differenzieren (Transdifferenzierung). Diese Prozesse spielen zum Beispiel bei der Wundheilung eine Rolle. Bei Krebs tritt die Entdifferenzierung in Form der dort zu beobachtenden Anaplasie auf. In Pflanzen finden sich ebenfalls auf die Teilung und damit die Erzeugung neuer Zellen und Gewebe spezialisierte, sogenannte meristematische Zellen, allerdings sind auch ausdifferenzierte Zellen häufig nicht oder nur eingeschränkt determiniert und behalten die Fähigkeit, sich unter bestimmten Umständen, zum Beispiel nach Verwundung, erneut zu teilen und verschiedene Zelltypen hervorzubringen.
Sources: de.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。
目前认为它可能通过Toll样受体等模式识别受体传递信号，但精确的受体身份和结合机制尚未完全阐明。
不同试验在患者选择、给药方案、联合治疗和终点定义上差异很大。这些异质性使得跨研究比较困难，结论难以统一。